NFKB1 and neoplasm: Since the proteasome pathway is important for activating NF-κB (25), the ability of a proteasome inhibitor to inhibit the NF-κB pathway by blocking proteasome degradation of IκB plays a key role in the activity of this agent against tumor cells (47–49).